Search Results
Your search for ,maY matches 17054 pages
Showing 12051 - 12100ASCO Endorses Cancer Care Ontario Recommendations on Decision-Making in Adjuvant Systemic Therapy for Early-Stage, Operable Breast Cancer
As reported in the Journal of Clinical Oncology by N. Lynn Henry, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and colleagues, ASCO has endorsed Cancer Care Ontario (CCO) guideline recommendations on the role of patient and disease factors in decisions on adjuvant systemic...
Lower Vitamin D Levels Associated With Adverse Pathology at Prostatectomy in Men With Localized Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Nyame et al found that lower serum 25-hydroxyvitamin D (25-OH D) levels were associated with an increased likelihood of adverse pathology at radical prostatectomy in men with localized prostate cancer. Study Details The cross-sectional...
Increased Frequency of BRCA Mutation Testing in Young Women With Breast Cancer
Rosenberg et al found that the proportion of women diagnosed with breast cancer at age ≤ 40 years who have undergone BRCA1 and BRCA2 testing has increased during recent years. These findings, which were reported in JAMA Oncology, were part of the ongoing prospective Helping Ourselves, Helping...
Study Finds Adaptive Image-Guided Radiation Therapy for Bladder Preservation Clinically Feasible in Urinary Bladder Cancer
A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy found that the bladder preservation rate at 3 years was 83%. These findings were published by Murthy et al in the International Journal ...
Endoscopic Mucosal Resection Is an Alternative to Surgery in Most Patients With Complex Colon Polyps
Using the latest advances in endoscopic resection techniques, more than 75% of patients with complex colon polyps could avoid surgery for their polyp removal, according to new research from The University of Texas MD Anderson Cancer Center. The findings, published by Raju et al in Gastrointestinal ...
Danish Study Shows Increased Risk for Cancers in Addition to Breast Cancer in CHEK2 Mutation Heterozygotes
In a study reported in the Journal of Clinical Oncology, Näslund-Koch et al found an increased risk for cancers in addition to breast cancer in individuals heterozygous for the CHEK2*1100delC germline mutation associated with an increased breast cancer risk. CHEK2 is a cell-cycle checkpoint...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues, ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder cancer. ...
PET Probe [18F]CFA Detects Deoxycytidine Kinase Activity, May Lead to New Ways to Improve Response to Treatment
A promising new discovery by University of California, Los Angeles (UCLA) scientists could lead to a new method of identifying cancer patients whose disease expresses high levels of an enzyme and who are more likely to respond to particular treatments. Their findings were published by Kim et al in...
Therapeutic Combinations May Prevent Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
In preclinical studies, breast cancer cells became resistant to therapeutics targeting CDK4/6, such as palbociclib (Ibrance), in multiple ways. According to the research published by Herrera-Abreu et al in Cancer Research, different combinations of therapeutics might prevent and overcome the...
Meta-analysis of Gene-Expression Datasets Identifies Novel Five-Gene Pancreatic Cancer Classifier
Pancreatic cancer is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) identified and validated an accurate five-gene classifier for discriminating early pancreatic cancer from nonmalignant...
Survivors of Adolescent and Young Adult Cancer May Be at Increased Risk of Cardiovascular Disease
Survivors of adolescent and young adult cancer were at a greater than twofold increased risk for cardiovascular disease than their counterparts without cancer, according to a study reported in the Journal of Clinical Oncology by Chao et al. Study Details The study involved data from a...
Italian Study Suggests Benefit of Interim PET Response–Adapted Therapy in High-Risk Advanced Hodgkin Lymphoma
The phase II portion of the Italian HD0801 study suggests that treatment based on positron-emission tomography (PET) performed early in first-line therapy for advanced Hodgkin lymphoma may improve outcome in patients at risk of first-line treatment failure. Zinzani et al reported their findings in...
ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Women With Early-Stage Invasive Breast Cancer
As reported in the Journal of Clinical Oncology by Harris et al, ASCO released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with early-stage invasive breast...
Low-Magnitude, High-Frequency Mechanical Stimulation May Improve Bone Mineral Density in Young Childhood Cancer Survivors
In a small trial reported in JAMA Oncology, Mogil et al found that low-magnitude, high-frequency mechanical stimulation improved the whole-body bone mineral density score in childhood cancer survivors with low bone mineral density. Study Details In the double-blind trial, 65 survivors of...
Minimal Residual Disease in AML: Worth Looking?
As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML)...
Quality Improvement Projects Aim at Reducing Errors in Prescribing IV and Oral Chemotherapy
Two quality improvement projects described in the Journal of Oncology Practice resulted in reduced errors in prescribing intravenous (IV) and oral chemotherapy. A project at the University of Texas Medical Branch in Galveston outpatient infusion centers first identified 15 different types of...
Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes
Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment...
Long Noncoding RNA SAMMSON Linked to Malignant Melanoma
In collaboration with researchers from Ghent University, Vlaams Instituut voor Biotechnologie (VIB) scientists from the University of Leuven have revealed a remarkable link between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is specifically expressed in human...
Survival Differs With Metastatic Site in Castration-Resistant Prostate Cancer
Overall survival differed according to the site of metastases in men with castration-resistant prostate cancer, according to a meta-analysis reported in the Journal of Clinical Oncology by Halabi et al. Study Details The study involved data from 8,820 men who received docetaxel chemotherapy in...
Study Finds Apitolisib Less Effective Than Everolimus in Metastatic Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology by Powles et al, the dual PI3K/mTOR inhibitor apitolisib was inferior to the mTOR inhibitor everolimus (Afinitor) in progression-free survival in a phase II trial in patients with metastatic clear cell renal cell carcinoma progressing on or after...
Study Explores Genomic and Transcriptomic Features of Anti–PD-1 Resistance in Advanced Melanoma
Immunotherapy using anti–programmed cell death 1 (PD-1) antibodies has revolutionized the treatment of advanced melanoma and a growing list of other cancers. But 60% to 70% of melanoma tumors are resistant to anti–PD-1 antibodies, and there is an urgent need to understand how to...
Assessment of Survival Impact of Atypical Responses With Pembrolizumab Treatment in Advanced Melanoma
As reported by Hodi et al in the Journal of Clinical Oncology, use of conventional Response Evaluation Criteria in Solid Tumors (RECIST) to assess response may have underestimated the benefit of treatment with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) in the...
ASCO Issues Report on State of Cancer Care in America: 2016
The State of Cancer Care in America: 2016, published online in the Journal of Oncology Practice1 and presented earlier this month at a Congressional briefing in Washington, DC, is ASCO’s third annual assessment of national trends in cancer care delivery. The report highlights many promising cancer...
I Never Forget I Have Cancer
I have a history of fibrocystic breasts, which required biopsies to make certain the cysts were benign, and for years they were. But in 2009, my mammogram screening picked up a suspicious lump in my right breast, which turned out to be stage III estrogen receptor–positive/progesterone...
Expect Questions and Heightened Interest About Bilateral Mastectomy
Recently released data from the Agency for Healthcare Research and Quality (AHRQ) showed that the rate of mastectomies increased between 2005 and 2013, with much of that increase attributed to bilateral mastectomies among women with early-stage cancer in one breast opting for bilateral...
The Perplexing Increase in Bilateral Mastectomies
The increased rate of bilateral mastectomies, as shown in recently released data from the Agency for Healthcare Research and Quality (AHRQ), is “perplexing,” Ismail Jatoi, MD, PhD, told The ASCO Post. “We are seeing more and more women with unilateral breast cancer opt for bilateral mastectomy,...
A Hard Look at the Connection Between Germs and Mental Illness
The relationship between disease and microbes was first proposed in the 17th century, but the basic standards for proving that infection causes disease were not laid down until 1883, when the German bacteriologists Robert Koch and Friedrich Loeffler provided the first evidence of the processes...
A Doctor’s Prescription for a Long Life
Longevity is a common goal among humans. And like all things human, it is not distributed equally. According to world health data, Japan is number one on the longevity list; its 130 million citizens have a life expectancy of about 84.74 years. The sub-Saharan country of Chad is number 224, having ...
A Gene Hunter’s Advice on How to Take Control of Your Genetic Inheritance
Since the late 1970s, researchers have identified several gene mutations that are implicated in cancer. Many of these mutations are acquired during our lifetime, but, as we know, some are inherited in families. Identifying heritable cancer-causing genetic mutations is a double-edged sword,...
2016 Oncology Meetings
MARCH 2016 Methods in Clinical Research Workshop for Minority PhysiciansMarch 17-20 • Fort Lauderdale, FloridaFor more information:https://www.roswellpark.edu/education/diversity-clinical-research-workshop The 16th Multidisciplinary Management of Cancers: A Case-Based ApproachMarch 18-20 • Napa,...
Benefiting From Mind-Body Therapy
My diagnosis of early-stage breast cancer at age 35 was a shock, also because I come from a family with no history of cancer. In disbelief, I was literally speechless—I lost my voice completely for several days. I grew up in the former Soviet Union and then in the newly independent Kyrgyzstan. My...
Expert Point of View: Carlos Arteaga, MD
Carlos Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said, “Breast-conserving therapy is the right thing to do. This study will not change current practice guidelines. Mastectomy is generally reserved for larger tumors and those with multifocal disease. The study just...
‘Know Your Tumor’ Program Aids Patients With Pancreatic Cancer
Patients with pancreatic cancer can obtain molecular tumor profiling through the Pancreatic Cancer Action Network’s Know Your TumorSM precision medicine initiative, a partnership with Perthera, a personalized medicine service company that facilitates the multi-omic profiling and generates the...
Studies Evaluate Bevacizumab-Containing Regimens in Metastatic Colorectal Cancer
Two trials reported at the 2016 Gastrointestinal Cancers Symposium evaluated bevacizumab (Avastin)-containing regimens in the first-line treatment of metastatic colorectal cancer and supported some, but not all, previous findings. The STEAM trial found some numerical differences but no...
Biomarkers in Prostate Cancer: PARP Inhibitors and Defects in DNA Repair
New data on molecular biomarkers in advanced prostate cancer are accumulating at a fast pace. The studies in this area can now be broadly grouped in two distinct areas—those that broadly relate to androgen signaling and those that relate to DNA-repair pathways. The Androgen-Signaling Pathway With...
Introduction of New Diagnostic Devices in Oncology: New Is Not Necessarily Better
“New!” “Improved!” “Throw out that old [fill in the blank] and go buy a new [fill in the blank]!” Sound familiar? The key to marketing is to convince customers that they need a product without which they had previously been quite happy. All too often, this strategy is accompanied by a caveat emptor ...
Potential Overdiagnosis of Contralateral Breast Cancer With Preoperative Breast MRI in Older Women With Breast Cancer
In an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database reported in the Journal of Clinical Oncology, Shi-Yi Wang, MD, PhD, of Yale School of Public Health, and colleagues found that the use of preoperative magnetic resonance imaging (MRI) was associated with...
How Rehabilitation Services Provide Benefit for Patients With Spinal Metastases
The benefits of rehabilitation in traumatic spinal injuries are well established. Recently, studies have shown similarly positive results in cancer-related spinal injuries, indicating that rehabilitation can play a complementary role in the care management of this patient population....
Modified CAR T Cells Overcome Immune Suppression, Effective Against Solid Tumors in Preclinical Models
Adding a genetically engineered “switch receptor” to second-generation CAR T cells blocked PD-1–mediated immune suppression, and made the immunotherapy effective against solid tumors in preclinical models, according to a study published by Liu et al in Cancer Research....
Occult Metastasis on Immunohistochemistry May Affect Survival in Stage I NSCLC
Mature results of the Cancer and Leukemia Group B 9761/Alliance study, reported in the Journal of Clinical Oncology by Martin et al, indicate that occult metastases detected by immunohistochemistry in N2 lymph nodes may be associated with poorer overall survival after resection in clinical stage I...
Closing the Clinical Trial Gap for Adolescents and Young Adults With Cancer
Although overall survival rates for patients with cancer continue to soar—with 14.5 million cancer survivors today1—most of that gain is among pediatric and older adult patients. For adolescents and young adults with cancer—defined by the National Cancer Institute (NCI) as those in the 15- to...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
Is This the Dawn of Cancer Biosimilars?
The Patient Protection and Affordable Care Act, signed into law in 2010, did more than make it possible for millions of Americans to afford health care; it also established an abbreviated approval pathway for biologic products that are “biosimilar” to, or shown to be “interchangeable” with, a U.S....
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Conquering Cancer With Dr. Kim
There are many different ways to treat cancer: surgery, radiation therapy, chemotherapy, and more, sometimes used alone and sometimes in combination. But, in certain circumstances, the best treatment option for a patient may not look much like treatment at all. Instead of attempting to eliminate...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Douglas A. Levine, MD, FACOG, FACS, Appointed Director of Gynecologic Oncology at NYU Langone
Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016. Dr. Levine brings an exceptional...
Expert Point of View: David Raben, MD
“Proton therapy may very well offer reduced late toxicities. Reflecting back on past reirradiation studies both within and outside of the cooperative groups, it seems that the late toxicities in this retrospective study were somewhat similar,” said David Raben, MD, Professor of Radiation Oncology...
Markedly Improved Toxicity Rates With Proton-Beam Reirradiation for Recurrent Head and Neck Cancer
Proton-beam radiation therapy may be an attractive option for reirradiation of recurrent head and neck cancer, with encouraging disease control and survival rates and improved toxicity rates compared to photon reirradiation, according to John Han-Chih Chang, MD. Most head and neck cancers present...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
